Zdrowie i gospodarka · 17.09.2009
Draft Guidance for Industry on Microbiological Data for Systemic Antibacterial Drug Products-Development, Analysis, and Presentation; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Microbiological Data for Systemic Antibacterial Drug Products-- Development, Analysis, and Presentation." The draft guidance informs industry of FDA's current thinking regarding the types of microbiological studies, assessments, and clinical trials needed to support an investigational new drug application (IND) and a new drug application (NDA) for a systemic antibacterial drug product. Recommendations in this guidance cover microbiological considerations in the three major areas of conducting general nonclinical studies; conducting animal and human studies and clinical trials; and establishing and updating in vitro susceptibility test methods, quality control (QC) parameters, and interpretive criteria. This guidance also recommends the content and format for presentation of microbiological data for antibacterial drug products in the Microbiology subsection of labeling.